Molecular imaging of akt enables early prediction of response to molecular targeted therapy

Area of Science:

• Oncology
• Molecular Imaging
• Cancer Therapy

Background:

• Individualized therapy requires real-time tools to assess treatment response.
• Molecular imaging sensors for Akt and caspase-3 activity have been previously developed.

Purpose of the Study:

• To evaluate the utility of Akt and caspase-3 molecular imaging reporters in assessing tumor responsiveness to a combination therapy.
• To compare two different administration schedules of gemcitabine and cetuximab in human head and neck cancer xenografts.

Main Methods:

• Utilized noninvasive molecular imaging sensors for Akt and caspase-3 activity.
• Administered combination therapy of gemcitabine (Gem) and cetuximab (Cet) in two distinct schedules.
• Monitored tumor volumes and molecular reporter activity over time.
• Employed Wilcoxon two-sample tests for statistical analysis.

Main Results:

• Human head and neck cancer xenografts showed significantly better response when cetuximab was administered after gemcitabine.
• Differences in tumor volume between schedules became significant on day 7.
• Differences in Akt activity became significant on day 4, preceding tumor volume changes.
• Molecular imaging of Akt activity allowed for earlier detection of therapy response (2 days prior to tumor volume).
• No significant difference in caspase-3 activity was observed between the schedules.

Conclusions:

• Molecular imaging of Akt activity can serve as an early indicator of therapeutic efficacy.
• This study provides a proof-of-concept for using Akt imaging to predict treatment response in head and neck cancer.
• Optimizing drug administration schedules is crucial for effective cancer therapy.